Skip Navigation

Annals of Oncology 2009 20(4):603; doi:10.1093/annonc/mdp205
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

in this issue

in this issue

The first 10% of the full text of this article appears below.


   LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer
 
Standard chemotherapy for patients with stage III colon cancer is monthly 5-fluorouracil (5-FU) combined with leucovorin (LV) for 6 months. Previously developed in metastatic colorectal cancer (MCRC), the semimonthly LV5FU2 regimen has been compared with the monthly 5FULV in the adjuvant setting and showed no statistically significant difference in overall survival but showed a better safety profile. The combination of irinotecan . . . [Full Text of this Article]


   Carboplatin–etoposide for docetaxel-pretreated castration-resistant prostate cancer
 

   IPI predicts outcome in aggressive adult T-cell leukemia/lymphoma
 

   CAM usage in adult cancer patients in Singapore
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
M. Ychou, J.-L. Raoul, J.-Y. Douillard, S. Gourgou-Bourgade, R. Bugat, L. Mineur, F. Viret, Y. Becouarn, O. Bouché, E. Gamelin, M. Ducreux, T. Conroy, J.-F. Seitz, L. Bedenne, and A. Kramar
Ann Oncol 2009 20: 674-680. [Abstract] [Full Text]  

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features
Y. Loriot, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, A. Bossi, and K. Fizazi
Ann Oncol 2009 20: 703-708. [Abstract] [Full Text]  

The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project
J. Suzumiya, K. Ohshima, K. Tamura, K. Karube, N. Uike, K. Tobinai, R. D. Gascoyne, J. M. Vose, J. O. Armitage, D. D. Weisenburger, and for the International Peripheral T-cell Lymphoma Project
Ann Oncol 2009 20: 715-721. [Abstract] [Full Text]  

Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients
V. Shih, J. Y. L. Chiang, and A. Chan
Ann Oncol 2009 20: 752-757. [Abstract] [Full Text]